Peter Michael Rademacher

Title: Peter Michael Rademacher: Innovator in Ferroportin Inhibitors

Introduction

Peter Michael Rademacher is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that act as ferroportin inhibitors. With a total of 3 patents to his name, Rademacher's work is paving the way for advancements in treating iron metabolism disorders.

Latest Patents

Rademacher's latest patents focus on cycloalkyl pyrimidines as ferroportin inhibitors. The subject matter described in these patents is directed to ferroportin inhibitor compounds of Formula I or I' and pharmaceutical salts thereof. These patents detail methods of preparing the compounds, pharmaceutical compositions comprising the compounds, and methods of administering the compounds for the prophylaxis and treatment of diseases caused by a lack of hepcidin or iron metabolism disorders. This includes conditions such as thalassemia, sickle cell disease, hemochromatosis, and kidney injuries.

Career Highlights

Peter Michael Rademacher is currently employed at Global Blood Therapeutics, Inc. His work at this company has allowed him to collaborate with other talented professionals in the field. His innovative approach to drug development has garnered attention and respect within the pharmaceutical community.

Collaborations

Some of Rademacher's notable coworkers include Zhe Li and Calvin Wesley Yee. Their collaborative efforts contribute to the ongoing research and development of effective treatments for patients suffering from iron metabolism disorders.

Conclusion

Peter Michael Rademacher is a distinguished inventor whose work in ferroportin inhibitors is making a significant impact in the pharmaceutical industry. His contributions are essential for advancing treatments for various iron-related health issues.